Silodyx 8 mg hard capsules
Spain
Table of Contents
Package leaflet: Information for the user
Introduction
Package leaflet: information for the patient
Silodyx 8 mg hard capsules
Silodyx 4 mg hard capsules
Silodosin
Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.
- Keep this leaflet, as you may need to read it again.
- If you have any questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only, and you should not give it to other people, even if they have the same symptoms as you, because it may harm them.
- If you experience any adverse effects, consult your doctor or pharmacist, even if these are adverse effects not listed in this leaflet. See section 4.
Contents of the leaflet:
- What Silodyx is and what it is used for
- What you need to know before taking Silodyx
- How to take Silodyx
- Possible side effects
- How to store Silodyx
- Contents of the pack and other information
1. What Silodyx is and what it is used for
What Silodyx is
Silodyx belongs to a group of medicines called alpha-1A adrenergic receptor blockers.
Silodyx is selective for receptors located in the prostate, bladder, and urethra. By blocking these receptors, it causes relaxation of the smooth muscle in these tissues. This makes it easier for you to urinate and relieves your symptoms.
What Silodyx is used for
Silodyx is used in adult men to treat urinary symptoms associated with benign enlargement of the prostate (benign prostatic hyperplasia, BPH), such as:
- difficulty starting to pass urine
- feeling of not completely emptying the bladder
- increased need to urinate, even at night
2. What you need to know before starting to take Silodyx
Do not take Silodyx
if you are allergic to silodosin or to any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Consult your doctor or pharmacist before starting to take Silodyx
-
If you are scheduled for eye surgery due to lens clouding (cataract surgery), it is important that you immediately inform your ophthalmologist that you are currently taking or have previously taken Silodyx. This is because some patients treated with this type of medication have experienced a loss of muscular tone in the iris (the colored circular part of the eye) during this type of surgery. The ophthalmologist can then take appropriate precautions regarding the medical and surgical techniques to be used. Ask your doctor whether it is necessary to delay or temporarily interrupt treatment with Silodyx prior to undergoing cataract surgery.
-
If you have ever fainted or felt dizzy upon standing suddenly, inform your doctor before taking Silodyx.
When taking Silodyx, dizziness and, occasionally, fainting may occur when standing up, especially at the beginning of treatment or if you are taking other medicines that lower blood pressure. If this happens, sit or lie down immediately until symptoms subside and inform your doctor as soon as possible (see also section “Driving and use of machines”).
-
If you have severe liver problems, you should not take Silodyx, as it has not been evaluated in this condition.
-
If you have kidney problems, consult your doctor.
If you have moderate kidney problems, your doctor will start treatment with Silodyx cautiously and may prescribe a lower dose (see section 3 “Dosage”).
If you have severe kidney problems, you should not take Silodyx.
-
Since benign enlargement of the prostate and prostate cancer can cause similar symptoms, your doctor will examine you to rule out prostate cancer before starting treatment with Silodyx. Silodyx is not intended for the treatment of prostate cancer.
-
Treatment with Silodyx may lead to abnormal ejaculation (reduced amount of semen expelled during sexual intercourse), which may temporarily affect male fertility. This effect reverses after discontinuation of Silodyx. Inform your doctor if you are planning to have children.
Silodyx contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per capsule; hence, it is essentially “sodium-free”.
Children and adolescents
Do not give this medicine to children or adolescents under 18 years of age, as there are no relevant indications for this age group.
Taking Silodyx with other medicines
Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.
In particular, inform your doctor if you are taking:
- medicines that lower blood pressure (especially alpha1-blockers such as prazosin or doxazosin), as there may be a potential risk that the effect of these medicines could be increased during use of Silodyx.
- antifungal medicines (such as ketoconazole or itraconazole), medicines used for HIV/AIDS infection (such as ritonavir), or medicines used after organ transplantation to prevent organ rejection (such as cyclosporine), as these medicines may increase blood levels of Silodyx.
- medicines used to treat difficulty in achieving or maintaining an erection (such as sildenafil or tadalafil), as their concomitant use with Silodyx may lead to a slight decrease in blood pressure.
- medicines for epilepsy or rifampicin (a medicine used to treat tuberculosis), as the effect of Silodyx may be reduced.
Pregnancy and breastfeeding
Silodyx is not indicated for use in women.
Fertility
Silodyx may reduce the amount of semen and temporarily affect your ability to father a child. If you intend to have a child, consult your doctor or pharmacist before using this medicine.
Driving and use of machines
Do not drive or operate machinery if you experience faintness, dizziness, drowsiness, or blurred vision.
3. How to take Silodyx
Follow exactly the instructions for use provided by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
The recommended dose is one 8 mg Silodyx capsule daily, taken orally.
Take the capsule always with food, preferably at the same time each day. Do not break or chew the capsule; swallow it whole, preferably with a glass of water.
Patients with renal problems
If you have moderate renal impairment, your doctor may prescribe a different dose.
For this purpose, Silodyx 4 mg hard capsules are available.
If you take more Silodyx than you should
If you have taken more than one capsule, inform your doctor as soon as possible. If you experience dizziness or feel weak, tell your doctor immediately.
If you forget to take Silodyx
You may take the capsule later the same day if you forgot to take it earlier. If it is almost time for your next dose, do not take the missed dose. Do not take a double dose to make up for the forgotten capsule.
If you stop taking Silodyx
If you discontinue treatment, symptoms may reappear.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
4. Possible adverse effects
Like all medicines, this medicine may cause adverse effects, although not everyone experiences them.
Contact your doctor immediately if you experience any of the following allergic reactions, as they could have serious consequences: swelling of the face or throat, difficulty breathing, feeling faint, skin itching, or hives.
The most common adverse effect is a reduction in the amount of semen released during sexual intercourse. This effect disappears after stopping treatment with Silodyx. Inform your doctor if you are planning to have children.
Dizziness, including dizziness upon standing, and occasionally fainting, may occur.
If you feel weak or dizzy, sit or lie down immediately until symptoms subside. If you experience dizziness upon standing or fainting, inform your doctor as soon as possible.
Silodyx may cause complications during cataract surgery (eye surgery due to lens clouding; see section “Warnings and precautions”).
It is important that you inform your ophthalmologist immediately if you are currently taking or have previously taken Silodyx.
The possible adverse effects are listed below:
Very common adverse effects (may affect more than 1 in 10 people)
- Abnormal ejaculation (a reduced or negligible amount of semen is expelled during sexual intercourse; see section “Warnings and precautions”)
Common adverse effects (may affect up to 1 in 10 people)
- Dizziness, including dizziness upon standing (see also above in this section)
- Nasal discharge or nasal congestion
- Diarrhoea
Uncommon adverse effects (may affect up to 1 in 100 people)
- Loss of sexual desire
- Nausea
- Dry mouth
- Difficulty achieving or maintaining an erection
- Increased heart rate
- Skin allergic reaction symptoms such as rash, pruritus, urticaria, and drug-induced rash
- Abnormal liver function test results
- Low blood pressure
Rare adverse effects (may affect up to 1 in 1,000 people)
- Rapid or irregular heartbeat (called palpitations)
- Fainting/Loss of consciousness
Very rare adverse effects (may affect up to 1 in 10,000 people)
- Other allergic reactions with swelling of the face or throat
Frequency not known (frequency cannot be estimated from available data)
- Floppy iris during cataract surgery (see also above in this section)
Inform your doctor if you notice that your sexual activity is affected.
Reporting of adverse effects
If you experience any adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You may also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.
5. Storage of Silodyx
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and blister pack following “EXP”. The expiry date refers to the last day of the month indicated.
Do not store above 30 °C.
Keep in the original packaging to protect from light and moisture.
Do not use this medicine if you notice that the packaging is damaged or shows signs of tampering.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines and packaging that you no longer need. This will help protect the environment.
6. Contents of the pack and other information
Composition of Silodyx
Silodyx 8 mg
The active substance is silodosin. Each capsule contains 8 mg of silodosin.
The other components are pregelatinized corn starch, mannitol (E421), magnesium stearate, sodium lauryl sulfate, gelatin, titanium dioxide (E171).
Silodyx 4 mg
The active substance is silodosin. Each capsule contains 4 mg of silodosin.
The other components are pregelatinized corn starch, mannitol (E421), magnesium stearate, sodium lauryl sulfate, gelatin, titanium dioxide (E171), yellow iron oxide (E172).
Appearance of the product and contents of the pack
Silodyx 8 mg are hard gelatin capsules, opaque and white in colour, size 0 (approximately 21.7 x 7.6 mm).
Silodyx 4 mg are hard gelatin capsules, opaque and yellow in colour, size 3 (approximately 15.9 x 5.8 mm).
Silodyx is available in packs of 5, 10, 20, 30, 50, 90 and 100 capsules, and in multiple packs containing 2 packs of 100 capsules each. Only certain pack sizes may be commercially available.
Marketing Authorization Holder
Recordati Ireland Ltd.
Raheens East
Ringaskiddy Co. Cork
Ireland
Manufacturer
Recordati Industria Chimica e Farmaceutica S.p.A.
Via Matteo Civitali 1
20148 Milan
Italy
Laboratoires Bouchara-Recordati
Parc Mécatronic
03410 Saint Victor
France
For further information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:
Belgium/Belgium/Belgium Recordati bv Tel/Tel: +32 2 461 01 36 | Lithuania Recordati Ireland Ltd. Tel: + 353 21 4379400 |
Recordati Ireland Ltd Tel.: + 353 21 4379400 | Luxembourg/Luxembourg Recordati bv Tél/Tel: +32 2 461 01 36 |
Czech Republic Recordati Ireland Ltd. Tel: + 353 21 4379400 | Hungary Recordati Ireland Ltd. Tel: + 353 21 4379400 |
Denmark Recordati Ireland Ltd. Tlf: + 353 21 4379400 | Malta Recordati Ireland Ltd. Tel: + 353 21 4379400 |
Germany Recordati Ireland Ltd. Tel: + 353 21 4379400 | Netherlands Recordati bv Tel: +32 2 461 01 36 |
Estonia Recordati Ireland Ltd. Tel: + 353 21 4379400 | Norway Recordati Ireland Ltd. Tlf: + 353 21 4379400 |
Greece BIANEX S.A. Tel: + 30 210 8009111 | Austria Recordati Ireland Ltd. Tel: + 353 21 4379400 |
Spain Almirall, S.A. Tel: +34 93 291 30 00 | Poland Recordati Ireland Ltd. Tel: + 353 21 4379400 |
France ZAMBON France Tél: + 33 (0)1 58 04 41 41 | Portugal Tecnimede Sociedade Técnico-Medicinal, S.A Tel: +351 21 041 41 00 |
Croatia Recordati Ireland Ltd. Tel: + 353 21 4379400 | Romania Recordati Ireland Ltd. Tel: + 353 21 4379400 |
Ireland Recordati Ireland Ltd. Tel: + 353 21 4379400 | Slovenia Recordati Ireland Ltd. Tel: + 353 21 4379400 |
Iceland Recordati Ireland Ltd. Sími: + 353 21 4379400 | Slovakia Recordati Ireland Ltd. Tel: + 353 21 4379400 |
Italy Takeda Italia S.p.A. Tel: + 39 06 502601 | Finland Recordati Ireland Ltd. Puh/Tel: + 353 21 4379400 |
Cyprus Recordati Ireland Ltd. Τηλ: + 353 21 4379400 | Sweden Recordati Ireland Ltd. Tel: + 353 21 4379400 |
Latvia Recordati Ireland Ltd. Tel: + 353 21 4379400 | United Kingdom (Northern Ireland) Recordati Ireland Ltd. Tel: + 353 21 4379400 |
Date of the most recent review of this leaflet
Other sources of information
Detailed information on this medicine is available on the website of the European Medicines Agency: http://www.ema.europa.eu.